Private Advisor Group LLC lowered its holdings in Shire PLC (NASDAQ:SHPG) by 50.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,711 shares of the biopharmaceutical company’s stock after selling 1,760 shares during the period. Private Advisor Group LLC’s holdings in Shire PLC were worth $279,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Hartford Financial Management Inc. boosted its holdings in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the last quarter. Stephens Inc. AR purchased a new position in Shire PLC in the first quarter valued at about $179,000. Pacer Advisors Inc. purchased a new position in Shire PLC in the second quarter valued at about $171,000. Quantbot Technologies LP purchased a new position in Shire PLC in the first quarter valued at about $182,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Shire PLC by 45.3% in the first quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 350 shares during the last quarter. 19.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ SHPG) opened at 153.40 on Thursday. Shire PLC has a 52-week low of $139.36 and a 52-week high of $206.94.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, analysts forecast that Shire PLC will post $14.93 earnings per share for the current fiscal year.
The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s payout ratio is currently 41.07%.
SHPG has been the subject of a number of analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $210.00 price target on shares of Shire PLC in a report on Thursday, July 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $222.00 price target on shares of Shire PLC in a report on Thursday, September 14th. HSBC Holdings plc raised Shire PLC from a “reduce” rating to a “hold” rating in a report on Thursday, July 6th. Jefferies Group LLC reissued a “buy” rating and issued a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a report on Friday, June 9th. Finally, Stifel Nicolaus reduced their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a report on Friday, June 9th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $220.08.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.